DK-2100 - København
Phone: +45 7020 0987
Name: Mads Nørregaard-Madsen
Position: Chief Innovation & Information Officer
Nuevolution is a Scandinavian biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. We have set our focus and objectives to be:
- Realization of efficacious, safer, tablet based, and lower cost medicines, for treatment of severe chronic inflammatory diseases like e.g. multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis (PsO), inflamed fatty liver (NASH) and chronic inflamed colon or intestine (IBD) where significant unmet medical need remains.
- Realization of programs enabling future medicines in immuno-oncology, effectively reactivating the cancer patient’s own immune system, when this has been ‘silenced’ by tumour cells.
- Realization of programs enabling personalized medicine (medicine fitting the individual patient) for treatment of cancer through identification of drugs, which selectively and safely eliminate the biological pathways upon which the tumour cells (of the individual patient) are dependent for survival and growth.